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Background: Application of continuous airway pressure (CPAP) in congestive heart failure (CHF) patients (pts) affected by obstructive sleep apnea 
(OSA) is associated with an improved prognosis. However, some OSA pts develop Cheyne-Stokes respiration (CSR) during CPAP treatment, a finding 
labelled as complex sleep apnea (complexSA). Aim of this study was to investigate effects of adaptive servoventilation (ASV) on cardiac function in 
CHF pts with complexSA.
Methods: In a total of 30 pts with CHF and stable medication, complexSA was documented by polysomnography (apnea-hypopnea-index (AHI) 
>15/h) during CPAP administration. ASV treatment (AutoSet CSII, ResMed™) was introduced in all pts. Echocardiography, cardiopulmonary exercise 
testing (CPX), measurement of hypercapnic ventilatory response (HCVR), 6-min walk test and measurement of NT-proBNP was performed at baseline 
and follow-up (14±4 mo).
Results: In 29 pts ASV treatment (34±15/h to 9±14/h) was primarily successful. During follow up 2 pts died (1 major cardiac event, 1 non-cardiac 
cause). 27 pts (26 males, 66±8 years) completed the study. AHI (34±15/h to 8±10/h, p<0.001), NYHA-class (2.7±0.7 to 2.0±0.9, p <0.001), NT-
proBNP concentration (1518±1267pg/ml to 1327±1667pg/ml, p=0.02), left ventricular (LV) ejection fraction (31.3±6.6% to 35.9±11.5%, p=0.03), 
HCVR (4.6±3.8l/min/mmHg to 3.1±2.2l/min/mmHg, p=0.03), oxygen uptake at aerobic/anaerobic threshold during CPX (12.6±3.6ml/min/kg 
to 14.3±3.8ml/min/kg, p=0.01), peak oxygen uptake (15.0±4.3ml/min/kg to 16.7±5.2ml/min/kg, p=0.01), and predicted peak oxygen uptake 
(61.2±18.2% to 71.3±23.2%, p=0.03) improved significantly during treatment. LV enddiastolic diameter (65.0±8.0mm to 63.2±13.6mm p=0.26) 
and 6-min walking distance (371±82m to 421±96m, p=0.09) tended to improve without reaching a significant level.
Conclusions: This is the first treatment study on CHF pts with complexSA. In our cohort ASV therapy was followed by a subjective improvement 
and increase of both exercise capacity and LV ejection fraction. Randomised, controlled outcome studies seem, however, mandatory before 
recommending ASV as an additional therapy in these pts.
